#United States #New York #securities lawsuit #Actinium #ATNM

Investor Alert: Class Action Lawsuit Against Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc. has recently come under scrutiny as Levi & Korsinsky, LLP has launched a class action lawsuit against the company. This legal battle stems from alleged securities law violations that could significantly impact investors who held shares during a specific period.

Background of the Case

The class action aims to recover losses for those who invested in Actinium between October 31, 2022, and August 2, 2024. Investors are encouraged to contact Levi & Korsinsky for more details and to understand their rights in this situation. The allegations suggest that the company misled shareholders regarding critical data from the Phase 3 Sierra trial, asserting that the messaging surrounding their therapeutic products was not only optimistic but potentially fraudulent.

Allegations Detailed

The lawsuit claims that Actinium made several false statements and concealed information that was crucial for an accurate understanding of the company's prospects. Specifically, it is alleged that:
1. Data from the Phase 3 Sierra trial was unlikely to meet FDA approval guidelines for the company’s product, Iomab-B;
2. Additional analyses presented to the FDA to improve perceptions of trial results were unlikely to adhere to the necessary standards;
3. There was a significant risk that the FDA would refuse to review Iomab-B's Biologics License Application (BLA) based on insufficient data;
4. The assertions made by Actinium’s leadership about the company’s potential and business stability were misleading and lacked a factual foundation.

These allegations, if proven, could raise serious questions about the company’s management and its transparency towards shareholders. Investors are reminded that the deadline to request to be appointed lead plaintiff is May 27, 2025. Even if individual investors do not wish to lead the lawsuit, they still may be entitled to a share of any financial recovery obtained through this litigation.

What to Do Next?

If you’ve experienced financial losses related to Actinium Pharmaceuticals, it's imperative to take action promptly. Contact Levi & Korsinsky to discuss your eligibility as a potential claimant in this class action. The firm has a solid track record in representing investors facing similar circumstances and offers a no-cost opportunity for class members to seek compensation without upfront fees.

Why Choose Levi & Korsinsky?

With over two decades of experience in the realm of securities litigation, Levi & Korsinsky has successfully recovered hundreds of millions for aggrieved investors. Our dedicated team of specialists is poised to navigate the complexities of these cases and advocate vigorously on behalf of our clients. Notably, the firm has consistently ranked among the top firms in securities litigation, further affirming our commitment to achieving justice for investors.

For those interested in understanding their legal positions better or participating in this class action, reach out to Levi & Korsinsky via email at [email protected] or call (212) 363-7500 for immediate assistance.

Conclusion

The Actinium Pharmaceuticals case serves as a reminder of the potential risks associated with investing, particularly in firms that may not be forthcoming with vital operational information. For shareholders, this is a crucial moment to assess their standing and take necessary measures to protect their investments. Staying informed and proactive is key to navigating the challenges presented by this lawsuit.